Comparative Pharmacology
Head-to-head clinical analysis: CALCIPARINE versus DICUMAROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CALCIPARINE versus DICUMAROL.
CALCIPARINE vs DICUMAROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Unfractionated heparin (UFH) potentiates antithrombin III (ATIII) activity, leading to inhibition of factor Xa and thrombin (factor IIa). It also binds to heparin cofactor II, inhibits platelet aggregation, and increases vascular permeability.
Dicumarol is a vitamin K antagonist that inhibits the synthesis of vitamin K-dependent clotting factors (II, VII, IX, X) and anticoagulant proteins C and S by blocking the reduction of vitamin K epoxide to vitamin K hydroquinone in the liver.
5000 IU subcutaneously twice daily for prophylaxis; 5000 IU intravenous bolus followed by 800-1000 IU/hour continuous intravenous infusion for treatment.
Initial oral dose 200-300 mg once daily for 2-3 days, then maintenance 25-200 mg once daily adjusted to target INR of 2.0-3.0 for most indications. Administered orally.
None Documented
None Documented
Terminal elimination half-life is approximately 1.5 hours (subcutaneous) after a 5000 IU dose. With therapeutic doses (e.g., 15,000 IU/24h), half-life may prolong to 2-3 hours. Clinical context: Half-life is dose-dependent and increases with heparin clearance saturation.
24–48 hours; prolonged in hepatic impairment or with CYP2C9 polymorphisms.
Primarily renal, with 40-60% of the dose excreted unchanged in urine. Minor biliary/fecal elimination (<10%).
Primarily renal as inactive metabolites; minimal biliary/fecal. ~95% renal, ~5% fecal.
Category C
Category C
Anticoagulant
Anticoagulant